Search results
Results from the WOW.Com Content Network
Hepatotoxicity (from hepatic toxicity) implies chemical-driven liver damage. Drug-induced liver injury (DILI) is a cause of acute and chronic liver disease caused specifically by medications and the most common reason for a drug to be withdrawn from the market after approval.
A hepatotoxin (Gr., hepato = liver) is a toxic chemical substance that damages the liver.. It can be a side-effect, but hepatotoxins are also found naturally, such as microcystins and pyrrolizidine alkaloids, or in laboratory environments, such as carbon tetrachloride, or far more pervasively in the form of ethanol (drinking alcohol).
Tolcapone has demonstrated significant liver toxicity (hepatotoxicity) [13] that limits the drug's utility. Entacapone is an alternative, largely since it has a more favorable toxicity profile. The hepatotoxicity can be related to elevated levels of transaminases , but studies have shown that minimal risk exists for those without preexisting ...
Download as PDF; Printable version; ... Drugs and other substances that have been associated with significant hepatotoxicity (liver damage). ...
Hy's law is a rule of thumb that a patient is at high risk of a fatal drug-induced liver injury if given a medication that causes hepatocellular injury (not Hepatobiliary injury) with jaundice. [1] The law is based on observations by Hy Zimmerman, a major scholar of drug-induced liver injury.
Notes: Many additional cases have been described in spontaneous adverse drug reaction reporting systems of individual countries. These include 19 cases (5 deaths) by late 1988 [ 3 ] and 96 cases (91 males, 5 females; 33 deaths) by early 1995 in the United Kingdom ; [ 41 ] [ 42 ] 32 cases (deaths not given) in Australia by 2004; [ 43 ] and 15 ...
You already know that drinking alcohol can wreak havoc on your liver. (And if you don't, well, here are more details on those dangers.) Now, a new study links a drink popular specifically for its ...
Drug-drug interactions can be of serious concern for patients who are undergoing multi-drug therapies. [5] Coadministration of chloroquine , an anti-malaria drug, and statins for treatment of cardiovascular diseases has been shown to cause inhibition of organic anion-transporting polypeptides (OATPs) and lead to systemic statin exposure.